论文部分内容阅读
目的:探讨联合吸入噻托溴铵和沙美特罗/氟替卡松对稳定期中重度慢性阻塞性肺疾病(COPD)患者肺功能的影响。方法:60例稳定期中重度COPD患者随机分成两组,治疗组给予噻托溴铵及沙美特罗/氟替卡松吸入治疗12周,对照组给予沙美特罗/氟替卡松吸入治疗12周,比较两组治疗前后肺功能主要指标变化及急性发作次数。结果:两组治疗后肺功能均明显改善,治疗组较对照组FEV1/FVC及FEV1占预计值百分比改善更明显(P<0.05);治疗后治疗组急性发作次数较对照组明显减少(P<0.05);两组不良反应发生率分别为14.3%和11.1%,差异无统计学意义(P>0.05)。结论:吸入噻托溴铵联合沙美特罗/氟替卡松更有效改善肺功能,减少患者急性发作次数。
Objective: To investigate the effects of combined inhalation of tiotropium bromide and salmeterol / fluticasone on pulmonary function in patients with stable chronic obstructive pulmonary disease (COPD). Methods: Sixty patients with moderate-to-severe COPD were randomly divided into two groups. The treatment group received tiotropium and salmeterol / fluticasone inhalation for 12 weeks, while the control group received salmeterol / fluticasone for 12 weeks. Before and after treatment Changes in the main indexes of lung function and the number of acute attacks. Results: The pulmonary function of the two groups were significantly improved after treatment. The FEV1 / FVC and FEV1 ratio in the treatment group improved more obviously than the control group (P <0.05). After treatment, the number of acute attacks in the treatment group was significantly lower than that in the control group (P < 0.05). The incidence of adverse reactions in both groups was 14.3% and 11.1% respectively, with no significant difference (P> 0.05). Conclusions: Inhaled tiotropium combined with salmeterol / fluticasone is more effective in improving lung function and reducing the number of acute episodes.